Advaxis (OTCMKTS:ADXS) Shares Pass Above Two Hundred Day Moving Average of $1.68
Advaxis (OTCMKTS:ADXS) Shares Pass Above Two Hundred Day Moving Average of $1.68
Shares of Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.68 and traded as high as $1.83. Advaxis shares last traded at $1.79, with a volume of 5,385 shares.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on Advaxis in a research report on Monday. They issued a "sell" rating on the stock.
Get Advaxis alerts:Advaxis Stock Performance
The firm has a market capitalization of $3.25 million, a price-to-earnings ratio of -0.20 and a beta of 2.44. The company has a 50 day moving average price of $1.73 and a two-hundred day moving average price of $1.68.
About Advaxis
(Get Rating)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Featured Articles
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.68 and traded as high as $1.83. Advaxis shares last traded at $1.79, with a volume of 5,385 shares.
在周三的交易中,Advaxis, Inc.(OTCMKTS: ADXS — Get Rating)的股价突破了其两百天移动平均线。该股的两百天移动平均线为1.68美元,交易价格高达1.83美元。Advaxis股票最后一次交易价格为1.79美元,成交量为5,385股。
Analyst Upgrades and Downgrades
分析师升级和降级
Separately, StockNews.com initiated coverage on Advaxis in a research report on Monday. They issued a "sell" rating on the stock.
另外,StockNews.com在周一的一份研究报告中开始了对Advaxis的报道。他们对该股发布了 “卖出” 评级。
Advaxis Stock Performance
Advaxis股票表现
The firm has a market capitalization of $3.25 million, a price-to-earnings ratio of -0.20 and a beta of 2.44. The company has a 50 day moving average price of $1.73 and a two-hundred day moving average price of $1.68.
该公司的市值为325万美元,市盈率为-0.20,beta值为2.44。该公司的50天移动平均线价格为1.73美元,两百天移动平均线价格为1.68美元。
About Advaxis
关于 Avaxis
(Get Rating)
(获取评分)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Advaxis, Inc是一家生物技术公司,从事癌症免疫疗法的发现、开发和商业化。它管理的平台技术利用活的减毒单核细胞增生李斯特菌分泌抗原或辅助融合蛋白。该公司拥有四个处于不同临床和临床前开发阶段的特许经营权,即:人乳头瘤病毒相关癌症、前列腺癌、新抗原疗法和热点突变疗法。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
- 免费获取 StockNews.com 关于 Advaxis (ADXS) 的研究报告的副本
- META 平台可能会迎来迄今为止最大的开盘价创下新高
- Penny stock Vinco Ventures 可能是
- 芯片设计专家 Synopsys 是隐藏在众目之中的宝石吗?
- 你应该在 Casey's General Stores 存放一些资金吗?
- Crowdstrike Stock:当铁杆很热的时候!
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Advaxis 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Advaxis及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧